iDoctus, Accelerating Digital Health to Grow 50% by 2021

iDoctus is relying on digitalization to continue developing. The Spanish company, which offers up-to-date diagnostic and treatment information that is easy to access, is confident of increasing its revenue by 50% in 2021, to $5.3 million (€4.5 million), as explained by Ángel Diaz, co-founder, and CEO of iDoctus.

The company closed 2020 with a turnover of $3.5 million (€3 million) and now plans to increase its business in the heat of the opportunities that Covid-19 has brought about in the sector. “We want to increase pharmaceutical coverage and be able to offer new services such as virtual doctor’s visits or electronic prescriptions,” said Diaz.

The application is designed for medical professionals and allows them to gain time and certainty in diagnosis, which has an impact on the quality of the service provided to patients. It offers up-to-date diagnostic and treatment information that is easy to access and allows the doctor to focus on what is most important: the patient.

Read more about iDoctus and find the latest financial news in the world with the Born2Invest mobile app.

iDoctus has more than 2,600 active ingredient and 16,000 drug files

In addition to specialized scientific information for medical use, the app includes a vademecum with the active ingredients and combinations, the drugs that are marketed, and up-to-date information on medical and pharmacological matters. It is useful when prescribing one drug or another depending on each patient and their clinical history because it helps to find the most appropriate and safe dosage and drug in each case.

iDoctus has more than 2,600 active ingredients and 16,000 drug files. The application also has more than 60 tools and scales, which help the physician to make decisions regarding patient management, automating calculations according to existing formulas and scales.

iDoctus is founded by two Spanish entrepreneurs trained at the Massachusetts Institute of Technology and Stanford University, Ángel Diaz and Luís Canizo, the latter being responsible for operations, as well as co-founder. Each of them controls 50% of the company.

The startup currently has a network of 480,000 doctors in Spain and Latin America, of whom 160,000 are from the Iberian country

The company has offices in Madrid, Barcelona and Mexico, the latter covering several Latin American countries. To date, iDoctus has invested $5.9 million (€5 million) in technology development and the platform. The company has a network of 480,000 doctors in Spain and Latin America. iDoctus also has the enGuardia app, launched in collaboration with the Spanish Society of Internal Medicine (Semi), so that doctors know what to do in urgent medical pathology.

This tool provides assistance to clinical physicians, those who specialize in adult patients from an integral point of view. This is a specialist who has extensive knowledge of different non-surgical medical specialties. enGuardia contains clinical, diagnostic, and treatment information on urgent pathology, with the aim of assisting the healthcare professional’s decision-making, especially during on-call and consultations.

__

(Featured image by kamleshverm via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.